Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Neutrophil lymphocyte ratio
Email alerts
Neutrophil lymphocyte ratio
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Ghayathri
Jeyakumar
,
Seongho
Kim
,
Naresh
Bumma
,
Craig
Landry
,
Cynthia
Silski
,
Stacey
Suisham
,
Brenda
Dickow
,
Elisabeth
Heath
,
Joseph
Fontana
,
Ulka
Vaishampayan
Journal for ImmunoTherapy of Cancer
Dec 2017,
5
(1)
82;
DOI:
10.1186/s40425-017-0287-5
Special collections
COVID-19
(37)
Editor's choice
JITC
Basic Tumor Immunology
(386)
Case Reports
(178)
Clinical Trials Monitor
(16)
Clinical/Translational Cancer Immunotherapy
(699)
Commentary/Editorials
(114)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(36)
Guidelines and Consensus Statements
(24)
Imaging and Immunotherapy
(2)
Immune Cell Therapies and Immune Cell Engineering
(115)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(281)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(91)
Reviews
(189)
Open access
(2336)
Press releases
